Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study

摘要: Summary Background Preliminary evidence suggests that magnesium wasting occurs in patients who are treated with epidermal-growth-factor receptor (EGFR)-targeting antibodies for colorectal cancer. The mechanism of this side-effect is unknown, and if all or a subset affected also unclear. We aimed to assess the incidence, characteristics, predictive factors during treatment EGFR-targeting antibodies, study pathophysiology phenomenon. Methods measured prospectively concentrations cohort 98 cancer without combined chemotherapy. primary outcome measure was slope serum over time. In 35 patients, 24-h urinary excretion measured. (n=5), an intravenous load test done. 16 had chemotherapy alone acted as controls. A clinical protocol written before initiation study, but because non-interventional not formally registered. Findings 95 (97%) decreasing compared baseline measurements. mean (with chemotherapy) significantly lower (−0·00157 mmol/L/day, SD 0·00162 [95% CI −0·00191 −0·00123] vs 0·00014 −00076 [−0·00026 0·00055]; ( t test, p Interpretation EGFR-inhibiting compromised renal retention capacity, leading hypomagnesaemia most patients. Future studies should address effects exposure target affinity. Our pivotal role EGFR-signalling pathway regulating homoeostasis.